Background Despite the proven efficacy and safety of apremilast to treat plaque psoriasis
(PsO), data regarding its real‐world use and patient‐perceived benefits are limited …

Abstract Introduction While several European studies have reported real-world apremilast
use, patient-perceived benefits, and treatment satisfaction, local reimbursement criteria for …

Abstract Introduction and Objectives: Patients (pts) with moderate plaque psoriasis are often
inadequately treated (Armstrong, 2013), and there remains an unmet medical need for an …

Background and objectives It is necessary to expand the knowledge in the use of apremilast
in clinical practice. The APPRECIATE study (NCT02740218) aims to describe the …

BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …

Introduction The broad and sustained efficacy of apremilast for psoriasis has been
demonstrated in randomized and real-world observational studies. Data from Central and …

Apremilast is a small molecule approved for the treatment of plaques psoriasis and adult
psoriatic arthritis. Pivotal studies have demonstrated short and long term efficacy and safety …

Introduction Apremilast is approved for the treatment of psoriasis and psoriatic arthritis.
However, data on the efficacy and safety of apremilast in clinical practice are limited. We …

Psoriasis is a chronic, inflammatory, immune‐mediated disease of the skin and joints.
Plaque psoriasis is the most common clinical phenotype of psoriasis. Apremilast is an oral …

Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …